SCHEMBL5582341

SCHEMBL5582341

CNc1ncc2c(-c3ccncc3)ccc(OC)c2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 1/20 0.45
ERN1 O75460 1/20 0.42
SLC2A1 P11166 1/20 0.41
NPC1 O15118 1/20 0.39
NTRK1 P04629 2/20 0.39
KIT P10721 1/20 0.39
PIK3CA P42336 1/20 0.39
TLR8 Q9NR97 2/20 0.39
PDGFRB P09619 3/20 0.38
PDGFRA P16234 3/20 0.38
CKS1B P61024 1/20 0.38
SKP2 Q13309 1/20 0.38
TLR7 Q9NYK1 1/20 0.36
CLK1 P49759 1/20 0.36
CLK2 P49760 1/20 0.36
CLK3 P49761 1/20 0.36
CDK5 Q00535 1/20 0.36
DYRK1A Q13627 1/20 0.36
CDK5R1 Q15078 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5582243 0.88 IDO1 (0.42) NPC1KITKMT2A
SCHEMBL5582139 0.86 NPC1 (0.54) NPC1KITPDGFRBPDGFRACKS1B
SCHEMBL5581786 0.86 ALDH1A1 (0.41) NTRK1KITPIK3CACLK4DYRK1B
SCHEMBL5582334 0.82 ALDH1A1 (0.40) PDE4DKITALDH1A1
SCHEMBL5581743 0.82 ALDH1A1 (0.40) PDE4DNPC1ALDH1A1CYP3A4
SCHEMBL5581811 0.80 PDGFRB (0.43) PDGFRBPDGFRADYRK1ACLK4ALDH1A1
SCHEMBL5582209 0.80 PTK2 (0.46) NPC1PTK2KDM4EMEN1ALDH1A1
SCHEMBL5582307 0.79 PDE4B (0.41) PDE4DNPC1ALDH1A1MAPT
SCHEMBL5582151 0.79 KIT (0.47) KITPDGFRBPDGFRA
SCHEMBL5581981 0.79 HPGDS (0.42) PDE4DKITBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225308-A1 2-Amino Quinazoline Derivative KYOWA HAKKO KOGYO CO.,LTD. (JP) 2007-09-27 US disclosed
EP-1726584-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225308-A1 2-Amino Quinazoline Derivative AGTR2, ABL1, AGTR1 PDE4D 1754/4885ERN1 3874/4885SLC2A1 2611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.